Human nk 92 cells

Manufactured by American Type Culture Collection

Human NK-92 cells are a natural killer cell line derived from the peripheral blood of a patient with non-Hodgkin's lymphoma. These cells exhibit characteristics of activated natural killer cells and can be used for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Hdmvec, by American Type Culture Collection (1 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions) Human umbilical vein ecs huvecs, by Lonza (1 mentions)

Spelling variants of this product

NK-92 (80 citations) NK-92 cells (29 citations)

3 protocols using human nk 92 cells

Culturing Human NK-92 and Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were cultured at 37°C in 5% CO₂. Human NK-92 cells (ATCC CRL2407) were obtained from ATCC (Manassas, VA) and cultured in α-Minimum Essential Medium (MEM) base medium supplemented with 12.5% fetal bovine serum (FBS), 12.5% horse serum, myo-inositol, folic acid, β-mercaptoethanol (β-ME), interleukin 2 (IL-2) and penicillin/ streptomycin, according to ATCC recommendations for complete growth medium. Human dermal microvascular endothelial cells (HDMVECs) were obtained from ATCC and cultured in Endothelial Growth Basal Medium (EBM)-2 base medium supplemented with the Microvascular Endothelial Cell Growth Medium-2 (EGM-2 MV) kit with FBS from Lonza (Allendale, NJ).

Mukherjee S., Kim J., Mooren O.L., Shahan S.T., Cohan M, & Cooper J.A. (2015). Role of Cortactin Homolog HS1 in Transendothelial Migration of Natural Killer Cells. PLoS ONE, 10(2), e0118153.

+ Open protocol

+ Expand

Culturing and Characterizing Endothelial Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were cultured at 37°C in 5% CO₂. Human dermal microvascular ECs (HDMVECs) and human umbilical vein ECs (HUVECs) were obtained from Lonza (Allendale, NJ). Primary human brain microvascular ECs (HBMECs) were obtained from ScienCell (Carlsbad, CA). A human brain microvascular cell line, CMEC/D3 [Daniels et al., 2013 (link)], was tested, but the cells did not express VE-cadherin and did not form monolayers, so they were not included in this study. Primary ECs were cultured in EBM-2 base medium supplemented with the EGM-2 kit for HUVECs or the EGM-2 MV kit for HDMVECs and HBMECs. HBMECs were not used after four passages; HDMVECs and HUVECs were not used after nine passages. Human PBLs were isolated as described [Mooren et al., 2014 (link)]. Human NK-92 cells (ATCC, Manassas, VA) were cultured as described [Mukherjee et al., 2014 ]. Human 92.1 uveal melanoma cells, a generous gift of Dr. Martine Jager (Laboratory of Ophthalmology, Leiden University), were grown in RPMI 1640 medium (Life Technologies, Carlsbad, CA) supplemented with 10% FBS and antibiotics.

Onken M.D., Mooren O.L., Mukherjee S., Shahan S.T., Li J, & Cooper J.A. (2015). Endothelial Monolayers and Transendothelial Migration Depend on Mechanical Properties of the Substrate. Cytoskeleton (Hoboken, N.J.), 71(12), 695-706.

+ Open protocol

+ Expand

Cell Culture Protocols for Various Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

293 cell line (ATCC No. CRL-1573) was cultured in Eagle's Minimum Essential Medium containing 10% fetal bovine serum and 100μg/ml gentamicin at 37°C with 5% CO₂. 293FT (Thermo Fisher Scientific Cat# R700-07) were cultured in D-MEM medium containing 10% FBS supplemented with 0.1 mM MEM Non-Essential Amino Acids, 1 mM sodium pyruvate, 2 mM L-glutamine and 500μg/ml Geneticin as “selective antibiotics”) at 37°C with 5% CO₂. Human cervical carcinoma Hela cells (ATCC No. CCL-2) were cultured in high-glucose DMEM containing 10% fetal bovine serum and 100μg/ml gentamicin at 37°C with 5% CO₂. Human NK92 cells (ATCC No. CRL-2407) were cultured in RPMI1640 media containing 20% fetal bovine serum, 100 μg/ml gentamicin and 100 IU Interleukin-2 (IL-2) (NK media) at 37°C with 5% CO₂.

Yang X., Yu X, & Wei Y. (2018). Lentiviral delivery of novel fusion protein IL12/FasTI for cancer immune/gene therapy. PLoS ONE, 13(7), e0201100.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!